Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.580
-0.015-0.27%
Volume:94.30M
Turnover:524.52M
Market Cap:104.25B
PE:36.88
High:5.715
Open:5.600
Low:5.505
Close:5.595
52wk High:9.017
52wk Low:4.190
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:0.71
T/O Rate:0.50%
Dividend:0.12
Dividend Rate:2.19%
EPS(LYR):0.151
ROE:14.07%
ROA:7.51%
PB:2.75
PE(LYR):36.88
PS:2.65

Loading ...

Sino Biopharmaceutical - Share Purchase Plan for an Aggregate Amount of Not Exceeding HK$2 Bln

THOMSON REUTERS
·
Jun 15

Sino Biopharmaceutical Stock Rallies 5.4% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jun 12

Movement Alert|China Grand Pharmaceutical Rises 3.14% in Regular Trading, Rebounding on ASCO Data and Sector Recovery

Market Focus
·
Jun 12

Movement Alert|Sino Biopharmaceutical Falls 3.08% in Regular Trading, Morgan Stanley Cuts Target Price Amid Pharmaceutical Sector Weakness

Market Focus
·
Jun 10

Aldeyra Therapeutics appoints Darlene Deptula-Hicks to board of directors

Reuters
·
Jun 10

Sino Biopharmaceutical Stock Slides 2.8% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jun 08

Innovative Drug Stocks Under Broad Selling Pressure as Liquidity Tightening Weighs on Valuations; Analysts View BINSA Bill Impact as Sentiment-Driven

Stock News
·
Jun 08

Movement Alert|Sino Biopharmaceutical Falls 3.22% in Regular Trading, Morgan Stanley Cuts Target Price Amid Broad Pharma Sector Weakness

Market Focus
·
Jun 08

Sino Biopharm (SBP Group) Cancels 40.35 Million Shares, Issued Capital Drops 0.22%

Bulletin Express
·
Jun 04

SBP GROUP Cancels 40.35 Million Repurchased Shares

Stock News
·
Jun 04

Sino Biopharmaceutical Stock Sheds 1.5% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jun 04

Movement Alert|Sino Biopharmaceutical Falls 3.14% in Regular Trading, Morgan Stanley Cuts Target Price Amid Pharma Sector Selloff

Market Focus
·
Jun 04

Movement Alert|Sino Biopharmaceutical Falls 3.07% in Regular Trading, Morgan Stanley Cuts Target Price Amid Broader Pharma Sector Selloff

Market Focus
·
Jun 03

Sino Biopharmaceutical Stock Slides 1.4% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jun 02

SBP Group Announces Phase II Data: Culmerciclib Achieves 32.4% ORR in CDK4/6i-Resistant HR+/HER2– Breast Cancer

Bulletin Express
·
Jun 02

SBP GROUP's Innovative Drug TQB3616 Displays Encouraging Clinical Outcomes in Resistant Breast Cancer at ASCO 2026

Stock News
·
Jun 02

Sino Biopharma says Phase II trial shows 32.4% response rate for culmerciclib combo in CDK4/6i-pretreated breast cancer patients at ASCO 2026

Reuters
·
Jun 02

Morgan Stanley Adjusts Target Price for SBP GROUP, Maintains Positive Outlook

Stock News
·
Jun 01

Movement Alert|Sino Biopharmaceutical Rises 3.21% in Regular Trading, Defu Combo Phase III Data Shows Head-to-Head Win in First-Line Non-Squamous NSCLC at ASCO

Market Focus
·
Jun 01

SBP GROUP (01177) Announces Phase III Clinical Data at 2026 ASCO for Bemusobart Combined with Anlotinib as First-Line Treatment in Non-Squamous NSCLC

Stock News
·
Jun 01